Core research objectives
- To expand knowledge and understanding of the advantages and disadvantages of the different approaches to assess clinical cost-effectiveness
- To consolidate the lessons from existing research, and to identify what new research would be of greatest value to improve HTA decision-making processes
- To advance the methodology in HTA by systematically exploring alternative means of assessing value for money and tracing the implications for the conduct of HTA and the use of cost-effectiveness data to inform decisionmaking regarding which health technologies to adopt
During the first two years of the project, WP1 has completed the following tasks:
- Creation of a classification for the main factors determining the HTA systems in the EU ranging from system-wide to product-specific variables.
- Construction of a database on cancer drug HTA for 8 EU countries.
- Empirical analysis of the main factors driving HTA decisions on cancer drugs for 8 countries.
During third and final year of the project, WP1 has completed the following tasks:
- Extended the dataset to 10 countries, followed by econometric analysis and interpretation of results.
- Extended the database to other therapeutic areas, in particular, Multiple Sclerosis and Rheumatoid Arthritis.
- Developed case studies to increase the value of the research, by deepening the empirical analysis of the full set of drugs and countries.
Why Do Some Countries Approve a Cancer Drug and Others Don't?
Principal Investigator: Professor John Cairns